Insider buying last 90 days
No open-market insider purchases were filed for HSIC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Henry Schein draws attention this week on an analyst upgrade to Buy and a round of coverage framing it as a growth and value candidate, including a comparison against Merit Medical on valuation grounds. The company also confirmed it will present at the Jefferies Healthcare Conference in London on 17 November and in New York on 1 December, keeping investor attention on upcoming appearances rather than new operating news.
Shares closed at $88.41, up 2.7% on the day, sitting above both the 50-day average of $86.11 and the 200-day average of $81.29, with the 50-day above the 200-day. The stock trades in the Neutral zone of the GekkoIndex, with a reading of 52.3 that has edged down 1.7 over five days. Price sits 6.3% above Gekko Fair Value of $83.2, and the one-year return stands at 26.2% versus a six-month gain of 28.1%.
The next earnings date falls on 23 February 2027, 105 days out, placing it outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the current windows, while one billionaire holder and one trailblazer holder are recorded among current positions. Seasonality from this point in the calendar has averaged a 4.1% gain over the next 20 trading days across 5 years, rising in 4 of them. Consensus among 10 firms stands at 6 buy, 3 hold, 1 sell, with a target of $96.93.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Henry Schein scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
Above 50 and 200-day
Close $86.22 is above the 50-day ($85.91) and 200-day ($81.52) averages, and the 50-day is above the 200-day.
See the chart57.2, Neutral
Reading 57.2 is in the Neutral zone.
See the GekkoIndex6.8% above
Price is 6.8% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 100 days
Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.
See earnings+6.3% on average
From this point in the calendar, the next 20 trading days averaged +6.3% over 5 years, rising in 4 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Henry Schein closed at $86.22 on Nov 13, 2026, +18.4% over the past year, inside a 52-week range of $68.70 to $92.18.
Use the left and right arrow keys to read daily values.
Put HSIC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Henry Schein provides a wide range of healthcare products and services to customers that include dental practices and labs, physician offices, government agencies, and other institutional and alternative care providers worldwide. It has built recognition around supplying dental items like infection control materials, impression materials, composites, anesthetics, and artificial teeth, plus tools such as handpieces, chairs, delivery systems, X-ray machines, and digital restoration equipment, along with protective gear and repair services for that equipment. It also moves a large volume of medical supplies, covering branded and generic drugs, vaccines, surgical tools, diagnostic kits, infection prevention items, imaging equipment, and nutritional products.
Its business is split into two segments. One, Health Care Distribution, centers on getting these dental and medical goods to customers along with repair work. The other, Technology and Value-Added Services, offers practice management software built for dental and medical providers, plus support like non-recourse financing, electronic tools, network and technology infrastructure help, hardware servicing, training programs, and consulting.
Henry Schein traces back to 1932 and runs its headquarters out of Melville, New York. Shares trade on the NASDAQ under the ticker HSIC.
Henry Schein’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.2, in the Neutral zone, up 2.6 points over five sessions.
Up 2.6 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 28 | +2.4% | +4.1% | ||
| Accumulation | 239 | +0.6% | +2.7% | ||
| Neutral (current zone) | 407 | −0.2% | −0.7% | ||
| Distribution | 27 | −0.2% | −2.1% | ||
| Selling | 1 | Too few readings yet | |||
Average HSIC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Henry Schein trades 6.8% above Gekko Fair Value of $80.73, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Henry Schein shares are worth, recalculated every trading day.
$80.73
Gekko Fair Value, Nov 14, 2026
6.8% Overvalued
At the end of Aug 2026 the price was 3.9% above the estimate.
No open-market insider purchases were filed for Henry Schein, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for HSIC in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in HSIC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Henry Schein has been buying back its own shares.
From company filings.
2of the funds Gekko tracks hold HSIC.
Henry Schein reports on Feb 23, 2027 (100 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 23, 2027
100 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 31, 2026 | $1.32 est $1.22 | $3.44B est $3.35B | +0.5% |
| Nov 4, 2025 | $1.38 est $1.27 | $3.34B est $3.34B | +11.4% |
| Aug 5, 2025 | $1.10 est $1.18 | $3.24B est $3.28B | −5.3% |
| May 5, 2025 | $1.15 est $1.11 | $3.17B est $3.22B | +1.4% |
| Feb 25, 2025 | $1.19 est $1.21 | $3.19B est $3.29B | −6.6% |
| Nov 5, 2024 | $1.22 est $1.17 | $3.17B est $3.36B | −3.2% |
| Aug 6, 2024 | $1.23 est $1.22 | $3.14B est $3.28B | −5.4% |
| May 7, 2024 | $1.10 est $1.01 | $3.17B est $3.21B | +6.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Henry Schein is $96.60, +12.0% from the last close, from 10 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 10 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 4 | Barclays | $100 | +16.0% |
| Nov 4 | BMO Capital | $85 | −1.4% |
| Nov 4 | Barrington | $104 | +20.6% |
| Nov 4 | Piper Sandler | $104 | +20.6% |
| Nov 4 | UBS | $95 | +10.2% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Henry Schein averaged +6.3% across the last 5 years, rising in 4 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.1% | 4 of 5 |
| Next 10 trading days | +1.6% | 3 of 5 |
| Next 15 trading days | +2.0% | 4 of 5 |
| Next 20 trading days | +6.3% | 4 of 5 |
| Next 30 trading days | +4.6% | 4 of 5 |
For scale, HSIC’s typical 20-trading-day move in either direction is about 4.6%.
Henry Schein’s market cap is $9.53B, with a P/E ratio of 23.6 and revenue of $13.73B over the last twelve months.
Coverage of Henry Schein this week reads neutral: 1 positive, 3 neutral and 0 negative headlines.
Henry Schein’s 3 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| MCKMcKesson | Distribution | 2.2% above |
| CORCencora | Neutral | 34.2% below |
| CAHCardinal Health | Distribution | 31.7% below |
A peer links to its own page where one exists.
Henry Schein’s market cap is $9.53B at the Nov 13, 2026 close of $86.22, with 110.5M shares outstanding. The shares trade on a P/E ratio of 23.6.
The consensus analyst 12-month price target for Henry Schein is $96.60, +12.0% from the last close. Of the 10 firms that rated the stock in the last 90 days, 6 rate it a buy, 3 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Henry Schein is overvalued: the Nov 13, 2026 close of $86.22 is 6.8% above Gekko Fair Value of $80.73. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Henry Schein is expected to report on Feb 23, 2027 (100 days away). Analysts expect earnings of $1.40 per share on revenue of $3.55B. Henry Schein beat the earnings estimate in 6 of its last 8 reports, moving 5% on average across the report.
Henry Schein’s 52-week high is $92.18 and its 52-week low is $68.70; it closed at $86.22 on Nov 13, 2026, +18.4% over the past year. Over the last five years the shares peaked at $92.68 on Apr 14, 2022.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.